The use of PSA as a first-line screening blood test came mainly from Catalona’s 1991 [6,7] and 1994 [7] trials, which compared digital rectal examination with PSA testing to detect PCa early and led to its approval as an aid to PCa early detection by the United States Food and Drug Administration (FDA). Here, KLK3 is linked to posterior cortical atrophy.